A to Z

GLP-1

·July 15, 2024·5 min read

Adjusting Proteins Increases Ozempic’s Effectiveness

Adjusting melanocortin proteins in the brain enhances the effectiveness of GLP-1 diabetes and weight-loss drugs. By inhibiting MC3R or activating MC4R, mice showed increased sensitivity to these drugs, leading to more significant weight loss and reduced feeding without additional side effects.

This shows a woman holding her head in pain.

Featured Neurology Neuroscience

·March 2, 2026·7 min read

Beyond Weight Loss: Ozempic Linked to Migraine Reduction

Unexpected relief. New research shows that patients taking GLP-1 drugs for diabetes or weight loss also experience fewer emergency room visits and need fewer medications for their chronic migraines.

Featured Neuroscience

·January 12, 2019·4 min read

Bile Acids Mediate Metabolic Benefits of Weight Loss Surgery

Researchers report bile acids play a key role in providing positive metabolic effects after weight loss surgery. The study also suggest the intestinal microbiome participates in post surgical improvements following gastric bypass. The findings could help develop new treatments for diabetes and obesity, researchers report.

Featured Neuroscience

·May 26, 2025·4 min read

Brainstem Neurons Hold Key to Semaglutide’s Weight Loss Effects

Researchers have identified a specific group of brainstem neurons that mediate the appetite-reducing and weight-loss effects of semaglutide without triggering side effects like nausea. In mice, activating these neurons led to reduced food intake and fat loss, mimicking the drug’s benefits.

This shows a brain and pills. One half of the brain is red, implying violence.

Featured Neuroscience Psychology

·June 17, 2026·8 min read

Can GLP-1 Medications Blunt the Path to Violence?

GLP-1 receptor agonists, such as Ozempic and Wegovy, may drastically reduce behaviors linked to violence.

Image shows trees cut to look like heads.

Featured Neurology Open Neuroscience Articles

·January 2, 2018·4 min read

Diabetes Drug ‘Significantly Reverses Memory Loss’ in Alzheimer’s: Mouse Study

Lancaster University researchers report a drug developed to treat diabetes shows promise in reversing memory loss associated with Alzheimer's in mouse models of the disease. The drug appears to have a neuroprotective effect, enhancing brain growth factors while reducing amyloid plaques, chronic inflammation and oxidative stress. The drug also slows down the rate of neuron loss.

This image shows a man eating a cookie and looking guilty.

Featured Genetics Open Neuroscience Articles

·July 26, 2015·4 min read

Eat For Pleasure Rather Than Hunger? You May Have a Hormone Deficiency

Do you prefer the taste of fatty food? Are you someone who eats for pleasure rather than for hunger's sake? According to a new study, the tendency to overeat could be due to a hormone deficiency.

Featured Neuroscience

·July 24, 2026·9 min read

Future Obesity Drugs to Target Specific Brain Circuits

Using site-specific knockout mouse models, researchers found that GIPR agonists suppress appetite via the brainstem, while GIPR antagonists act in the hypothalamus to release a "brake" on hindbrain satiety.

Featured Neuroscience

·May 16, 2024·6 min read

GLP-1 and NMDA Targeted Weight-Loss Drug Shows Promise

Researchers have developed a novel weight-loss drug that combines GLP-1 with molecules targeting NMDA receptors in the brain. This "Trojan Horse" approach allows the drug to specifically target the appetite control center, leading to significant weight loss in mice.

This shows a person holding their head in pain.

Featured Neurology Neuroscience

·June 24, 2025·3 min read

GLP-1 Drug Cuts Migraine Days in Half

A new study finds that the diabetes drug liraglutide significantly reduced monthly migraine days in patients with obesity and chronic migraine. Participants reported an average of 11 fewer headache days per month, alongside improved disability scores and quality of life.

Featured Neurology Neuroscience

·July 30, 2024·4 min read

GLP-1 Drug Slows Alzheimer’s Cognitive Decline

A recent study suggests that a GLP-1 drug, liraglutide, may protect the brains of people with mild Alzheimer’s disease, slowing cognitive decline by 18% over one year. This effect is likely due to the drug’s ability to reduce brain inflammation, improve insulin resistance, and lower the impact of Alzheimer’s biomarkers.

Featured Neuroscience

·May 12, 2026·7 min read

GLP-1 Drugs Dramatically Reduce “Food Noise” in Weight Loss

GLP-1 medications effectively "turn down the volume" on intrusive food thoughts. In a study of 417 adults, those combining medication with behavioral therapy saw a significantly greater reduction in "food noise" than those using therapy alone, offering a potential neurobiological explanation for the success of these new obesity treatments.

1 2 3

GLP-1

Adjusting Proteins Increases Ozempic’s Effectiveness

Beyond Weight Loss: Ozempic Linked to Migraine Reduction

Bile Acids Mediate Metabolic Benefits of Weight Loss Surgery

Brainstem Neurons Hold Key to Semaglutide’s Weight Loss Effects

Can GLP-1 Medications Blunt the Path to Violence?

Diabetes Drug ‘Significantly Reverses Memory Loss’ in Alzheimer’s: Mouse Study

Eat For Pleasure Rather Than Hunger? You May Have a Hormone Deficiency

Future Obesity Drugs to Target Specific Brain Circuits

GLP-1 and NMDA Targeted Weight-Loss Drug Shows Promise

GLP-1 Drug Cuts Migraine Days in Half

GLP-1 Drug Slows Alzheimer’s Cognitive Decline

GLP-1 Drugs Dramatically Reduce “Food Noise” in Weight Loss

PCOS/PMOS Increases Alzheimer’s Risk

Alcohol Tricks Brain Cells Into Destroying Themselves

Daytime Napping Linked to Higher Risk of Dementia

Prenatal Stress Alters the Placenta to Shape Fetal Brain Development

Subscribe